Login to Your Account



Abide with Me: Merck Paying up to $430M in Diabetes Deal

By Randy Osborne
Staff Writer

Friday, May 3, 2013
Abide Therapeutics Inc.'s potential $430 million deal with Merck & Co. Inc. is focusing on Type II diabetes by way of small molecules that take aim at members of the serine hydrolase enzyme family.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription